Clinical Trial Update: Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for tipifarnib in previously treated, advanced HRAS-mutant urothelial carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Tipifarnib (tipifarnib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Urothelial Carcinoma | Phase 2 | Status: UNKNOWN